UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Glioblastoma
The FRONTIER Study is a prospective, interventional, single-arm, multi-center study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Conditions
Glioblastoma
This is a phase 1/2 clinical trial evaluating the safety, tolerability, and preliminary antitumor activity of TNG456 as monotherapy and in combination with abemaciclib in patients with solid tumors with methylthioadenosine phosphorylase (MTAP) loss.
Conditions
Glioblastoma
Glioma
In this phase II study, researchers will study whether treatment with atezolizumab provides a therapeutic benefit for patients with recurrent glioblastoma and a low mutational burden.
Conditions
Glioblastoma
Glioma
This is randomized multi-site phase II clinical trial that aims to assess whether a ketogenic diet improves overall survival in newly diagnosed glioblastoma patients who receive standard of care treatment when compared to the standard anti-cancer diet.
Conditions
Glioma
Astrocytoma
Glioblastoma
Pleomorphic xanthoastrocytoma (grades II-III)
The phase I trial will evaluate the safety and efficacy of nivolumab and ipilimumab before and after surgery in treating children and young adults with recurrent or progressive high grade glioma.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This phase I/IIa study in patients with recurrent IDH-mutant glioma will investigate the safety and preliminary efficacy of AZD9574 in combination with temozolomide.
Conditions
Diffuse Midline Glioma
Glioma
Brainstem Glioma
This phase 1/2 trial is evaluating the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy to treat children and young adults with newly diagnosed high-grade gliomas (HGGs) that have alterations in the gene that encodes histone 3 (H3 K27-altered).
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
Neurofibromatosis type 1
This phase III clinical trial will compare the efficacy of selumetinib compared to standard treatment with carboplatin/vincristine (CV) in patients with NF1-associated low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will evaluate the efficacy of selumetinib compared to treatment with carboplatin/vincristine (CV) in patients with low-grade glioma (LGG).
Conditions
Glioma
Glioblastoma
Astrocytoma
Oligodendroglioma
This is an international, open-label phase II clinical trial for recurrent patients who have a glioma harboring a BRAF abnormality.
Conditions
Glioma
Glioblastoma
This phase II/III clinical trial is a response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM.
Conditions
Meningioma
This single center pilot trial is designed to demonstrate the safety of adjuvant hypofractionated stereotactic radiosurgery for patients after gross total of resection of intermediate risk meningioma.